A novel transcatheter tricuspid repair technology based on the clover surgical technique
DE BONIS M. (1), ALFIERI O. (1)
(1) Vita-Salute San Raffaele University, Metropolitan City of Milan ITALY
Company
StarTric is a startup based in Milan which is developing a minimally invasive implantable device for the repair of the Tricuspid heart Valve (TV) to treat Tricuspid Regurgitation (TR). StarTric technology is conceived as a transcatheter “replica” of the edge-to-edge Clover open surgery technique, pioneered by Ottavio Alfieri and Michele De Bonis, cardiac surgeons and scientists, and applied with success for many years. StarTric’s is a next generation technology, with respect to the current transcatheter TR therapies, conceived for high efficacy (comparable to that of the surgical Clover), wide indications, easiness of use and accessibility. Ottavio Alfieri and Michele De Bonis, along with Eugenio Passanante (CFO/COO) are co-founders of StarTric, Daniele Zanotti is the CEO.
